Human NOV/CCN3 Antibody
Human NOV/CCN3 Antibody Summary
Accession # P48745
Human NOV/CCN3 Sandwich Immunoassay
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
NOV/CCN3 in Human Kidney Cancer Tissue. NOV/CCN3 was detected in immersion fixed paraffin-embedded sections of human renal cancer tissue using Goat Anti-Human NOV/CCN3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1640) at 1.7 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Specific labeling was localized to the cytoplasm of epithelial cells. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
NOV, also called CCN3, is one of six CCN (CYR61/CTGF/NOV) secreted proteins which share a common multimodular organization (1-4). NOV/CCN3 contains an N‑terminal IGFBP domain that appears to be non-functional and a vWF type C and thrombospondin type I domain which mediate oligomerization and matrix interactions, respectively (1, 2). The C-terminal cysteine knot domain interacts with several partners, including the matrix protein fibulin 1C (5), Notch-1 (6), and CCN2, with which it may heterodimerize (2). NOV/CCN3 also interacts with the gap junction protein Connexin43 and mediates suppression of proliferation (7). It also binds the calcium binding protein S100A4 and promotes calcium channel activation (8). The 357 amino acid (aa), 44 kDa human NOV/CCN3 shares 80% aa identity with mouse, rat and dog NOV/CCN3, and 78% aa identity with cow NOV/CCN3. NOV/CCN3 also shows 38-50% aa identity with other family members including WISP proteins, except for WISP-2/CCN5 which lacks the cysteine knot (1). NOV/CCN3 is widely expressed developmentally, especially in muscle, endothelium, nervous system, adrenal cortex and chondrocytes (1-4). In transformed cells, a 32 kDa N-terminally truncated form lacks the signal sequence is localized to the nucleus. Truncation allows a C‑terminal nuclear localization sequence to be active (9). Nuclear NOV/CCN3 acts as a transcriptional repressor but promotes proliferation, presumably by interfering with growth control (9). Full length NOV/CCN3 is a secreted matricellular protein which inhibits cell growth. Interaction of NOV/CCN3 with integrins alpha v beta 3 and alpha 5 beta 1 mediates endothelial cell adhesion, chemotaxis, and promotes angiogenesis (10, 11). Over-expression of NOV/CCN3 downregulates myogenic genes such as MyoD (12).
- Perbal, B. (2004) Lancet 363:62.
- Perbal, B. (2006) Cell Commun. Signal. 4:3.
- Martinerie, C. et al. (1994) Oncogene 9:2729.
- Snaith, M.R. et al. (1996) Genomics 38:425.
- Perbal, B. et al. (1999) Proc. Natl. Acad. Sci. USA 96:869.
- Sakamoto, K. et al. (2002) J. Biol. Chem. 277:29399.
- Fu, C.T. et al. (2004) J. Biol. Chem. 279:36943.
- Li, C.L. et al. (2002) Mol. Pathol. 55:250.
- Planque, N. et al. (2006) J. Cell. Biochem. 99:105.
- Lin, C.G. et al. (2003) J. Biol. Chem. 278:24200.
- Lin, C.G. et al. (2003) J. Biol. Chem. 280:8229.
- Calhabeu, F. et al. (2006) Exp. Cell. Res. 312:1876.
Citations for Human NOV/CCN3 Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
Citations: Showing 1 - 4
Filter your results:
CCN3 is dynamically regulated by treatment and disease state in multiple sclerosis
Authors: M Naughton, J Moffat, G Eleftheria, N de la Vega, A Young, J Falconer, K Hawkins, B Pearson, B Perbal, A Hogan, P Moynagh, S Loveless, NP Robertson, B Gran, R Kee, S Hughes, G McDonnell, O Howell, DC Fitzgerald
J Neuroinflammation, 2020-11-22;17(1):349.
Sample Types: Cell Lysates, Whole Tissue
Applications: IHC, Western Blot
Osteoblasts are "educated" by crosstalk with metastatic breast cancer cells in the bone tumor microenvironment
Authors: AD Kolb, AB Shupp, D Mukhopadhy, FC Marini, KM Bussard
Breast Cancer Res., 2019-02-27;21(1):31.
Sample Types: Whole Cells, Whole Tissue
Applications: Functional Assay, IHC-P
Renal Fibrosis mRNA Classifier: Validation in Experimental Lithium-Induced Interstitial Fibrosis in the Rat Kidney
PLoS ONE, 2016-12-21;11(12):e0168240.
Sample Types: Whole Tissue
Matricellular protein CCN3 (NOV) regulates actin cytoskeleton reorganization.
Authors: Sin WC, Tse M, Planque N, Perbal B, Lampe PD, Naus CC
J. Biol. Chem., 2009-08-25;284(43):29935-44.
Sample Types: Cell Lysates, Whole Cells
Applications: ICC, Western Blot
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Human NOV/CCN3 Antibody
There are currently no reviews for this product. Be the first to review Human NOV/CCN3 Antibody and earn rewards!
Have you used Human NOV/CCN3 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image